{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:03:02Z","timestamp":1782878582014,"version":"3.54.5"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,4]]},"DOI":"10.7759\/cureus.16169","type":"journal-article","created":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T16:13:58Z","timestamp":1625415238000},"source":"Crossref","is-referenced-by-count":4,"title":["A Rare Case of Bullous Pemphigoid Secondary to Checkpoint Inhibitor Immunotherapy: A Tense Situation"],"prefix":"10.7759","author":[{"given":"Jacqueline T","family":"Wesolow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah D","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong J","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018, 6:8. 10.1186\/s40425-018-0316-z","journal-title":"J Immunother Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3747\/co.25.4235","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a brief review","volume":"25","author":"Myers G","year":"2018","unstructured":"Myers G. Immune-related adverse events of immune checkpoint inhibitors: a brief review. Curr Oncol. 2018, 25:342-7. 10.3747\/co.25.4235","journal-title":"Curr Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.02.007","article-title":"Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer","volume":"88","author":"Howell M","year":"2015","unstructured":"Howell M, Lee R, Bowyer S, Fusi A, Lorigan P. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. Lung Cancer. 2015, 88:117-23. 10.1016\/j.lungcan.2015.02.007","journal-title":"Lung Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid","volume":"94","author":"Miyamoto D","year":"2019","unstructured":"Miyamoto D, Santi CG, Aoki V, Maruta CW. Bullous pemphigoid. An Bras Dermatol. 2019, 94:133-46. 10.1590\/abd1806-4841.20199007","journal-title":"An Bras Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler AN","year":"2020","unstructured":"Geisler AN, Phillips GS, Barrios DM, et al.. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020, 83:1255-68. 10.1016\/j.jaad.2020.03.132","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management","volume":"23","author":"Lopez AT","year":"2018","unstructured":"Lopez AT, Geskin L. A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management. Oncologist. 2018, 23:1119-26. 10.1634\/theoncologist.2018-0128","journal-title":"Oncologist"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.06.033","article-title":"Skin biopsy: biopsy issues in specific diseases","volume":"74","author":"Elston DM","year":"2016","unstructured":"Elston DM, Stratman EJ, Miller SJ. Skin biopsy: biopsy issues in specific diseases. J Am Acad Dermatol. 2016, 74:1-16. 10.1016\/j.jaad.2015.06.033","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel J","year":"2018","unstructured":"Siegel J, Totonchy M, Damsky W, et al.. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol. 2018, 79:1081-8. 10.1016\/j.jaad.2018.07.008","journal-title":"J Am Acad Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.03.003","article-title":"Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis","volume":"6","author":"Qiu C","year":"2020","unstructured":"Qiu C, Shevchenko A, Hsu S. Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis. JAAD Case Rep. 2020, 6:400-2. 10.1016\/j.jdcr.2020.03.003","journal-title":"JAAD Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN Guidelines Insights: management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson JA","year":"2020","unstructured":"Thompson JA, Schneider BJ, Brahmer J, et al.. NCCN Guidelines Insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc Netw. 2020, 18:230-41. 10.6004\/jnccn.2020.0012","journal-title":"J Natl Compr Canc Netw"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.049","article-title":"Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients","volume":"81","author":"Polansky M","year":"2019","unstructured":"Polansky M, Eisenstadt R, DeGrazia T, Zhao X, Liu Y, Feldman R. Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients. J Am Acad Dermatol. 2019, 81:179-86. 10.1016\/j.jaad.2019.03.049","journal-title":"J Am Acad Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/60866-a-rare-case-of-bullous-pemphigoid-secondary-to-checkpoint-inhibitor-immunotherapy-a-tense-situation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:31:22Z","timestamp":1707507082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/60866-a-rare-case-of-bullous-pemphigoid-secondary-to-checkpoint-inhibitor-immunotherapy-a-tense-situation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,4]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.16169","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,4]]}}}